Cargando…

P878: HIGH MUTATIONAL BURDEN OF CHROMATIN MODIFYING GENES DEFINES A RELATIVELY INDOLENT SUBGROUP OF PLASMA CELL DYSCRASIAS

Detalles Bibliográficos
Autores principales:	Wang, X., Qiao, B., Yu, Y., Xu, J., Zuo, L., Chen, J., Cai, H., Han, H., Cao, X.-X., Sun, C., Li, J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429027/ http://dx.doi.org/10.1097/01.HS9.0000846388.33321.42

Ejemplares similares

Value of PET-CT in plasma cell dyscrasias: a literature and pictorial review
por: Aggarwal, R, et al.
Publicado: (2015)

Telomerase activity in plasma cell dyscrasias
por: Xu, D, et al.
Publicado: (2001)

Ocular complications of plasma cell dyscrasias
por: Singh, Rohan Bir, et al.
Publicado: (2023)

CCM 87.8
Publicado: (1987)

Crusted Scabies in Systemic Sclerosis with Plasma Cell Dyscrasia
por: Nikam, Balkrishna P., et al.
Publicado: (2018)

Opium Dyscrasia
por: Moore,
Publicado: (1886)

Pus Dyscrasia
por: Barrett, W. C.
Publicado: (1881)

878. Telemedicine Implementation in a Midwestern HIV Clinic: One Year Outcomes
por: Regan, Nichole N, et al.
Publicado: (2021)

A case of plasma cell dyscrasia presenting as nonscarring alopecia
por: Nia, Benjamin, et al.
Publicado: (2021)

Quantitation of Monoclonal Plasma Cells in Bone Marrow Biopsies in Plasma Cell Dyscrasia
por: Markey, G. M., et al.
Publicado: (2003)

The Non-Coding RNA Landscape of Plasma Cell Dyscrasias
por: Morelli, Eugenio, et al.
Publicado: (2020)

Pulmonary Vascular Disease Due to Plasma Cell Dyscrasia
por: Rajapreyar, Indranee, et al.
Publicado: (2020)

Imaging for Plasma Cell Dyscrasias: What, When, and How?
por: Guha, Amrita, et al.
Publicado: (2022)

Mutational landscape reflects the biological continuum of plasma cell dyscrasias
por: Rossi, A, et al.
Publicado: (2017)

Quantitative and qualitative assessment of plasma cell dyscrasias in dual-layer spectral CT
por: Brandelik, S. C., et al.
Publicado: (2021)

The potential role of curcumin (diferuloylmethane) in plasma cell dyscrasias/paraproteinemia
por: Golombick, Terry, et al.
Publicado: (2008)

How I treat elderly patients with plasma cell dyscrasias
por: Gavriatopoulou, Maria, et al.
Publicado: (2018)

Clinical and Biological Characteristics of Medullary and Extramedullary Plasma Cell Dyscrasias
por: Janjetovic, Snjezana, et al.
Publicado: (2021)

Leptomeningeal isolated infiltration in plasma cell dyscrasia associated to HIV
por: Sprenger, Flávia, et al.
Publicado: (2022)

Diagnostic and Therapeutic Considerations in Concurrent Plasma Cell Dyscrasia and Amyloidosis
por: Baljevic, Muhamed
Publicado: (2022)

COVID-19 vaccine immune response and plasma cell dyscrasia
por: Kleebayoon, Amnuay, et al.
Publicado: (2023)

Post-Arsphenamine Blood Dyscrasias
por: Rajam, R. V., et al.
Publicado: (1938)

Prospective Assessment of Tumour Burden and Bone Disease in Plasma Cell Dyscrasias Using DW-MRI and Exploratory Bone Biomarkers
por: Agarwal, Gaurav, et al.
Publicado: (2022)

The Role of the Gut Microbiome in Pathogenesis, Biology, and Treatment of Plasma Cell Dyscrasias
por: Jasiński, Marcin, et al.
Publicado: (2021)

Correlations between clinical and physiological consequences of the novel mutation R878C in a highly conserved pore residue in the cardiac Na(+) channel
por: Zhang, Y, et al.
Publicado: (2008)

C-src Enriched Serum Microvesicles Are Generated in Malignant Plasma Cell Dyscrasia
por: Di Noto, Giuseppe, et al.
Publicado: (2013)

Cutaneous Vasculitis: An Unusual Presentation of a Biclonal Nodal Plasma Cell Dyscrasia
por: Swan, D., et al.
Publicado: (2017)

NK cells and CD38: Implication for (Immuno)Therapy in Plasma Cell Dyscrasias
por: Zambello, Renato, et al.
Publicado: (2020)

Basic Aural Dyscrasia and Vascular Deafness
Publicado: (1887)

Basic Aural Dyscrasia and Vascular Deafness
Publicado: (1886)

P1653: CLINICAL EFFICACY AND SAFETY OF SWITCHING ELTROMBOPAG AND RH-TPO IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA DURING THE COVID-19 PANDEMIC
por: Cai, X., et al.
Publicado: (2022)

P878: SELINEXOR IN COMBINATION WITH DARATUMUMAB-BORTEZOMIB AND DEXAMETHASONE FOR THE TREATMENT OF RELAPSE OR REFRACTORY MULTIPLE MYELOMA: UPDATED RESULTS OF THE PHASE 2, MULTICENTER GEM-SELIBORDARA STUDY
por: Gonzalez-Calle, Veronica, et al.
Publicado: (2023)

Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines
por: Maura, F, et al.
Publicado: (2018)

P1465: INITIAL SAFETY AND EFFICACY STUDY OF RM-001, AUTOLOGOUS HBG1/2 PROMOTER-MODIFIED CD34+ HEMATOPOIETIC STEM AND PROGENITOR CELLS, IN TRANSFUSION-DEPENDENT ΒETA-THALASSEMIA
por: Wang, L., et al.
Publicado: (2022)

Correlation of plasma cell assessment by phenotypic methods and molecular profiles by NGS in patients with plasma cell dyscrasias
por: Rebmann Chigrinova, Ekaterina, et al.
Publicado: (2022)

Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias
por: Roccaro, Aldo M, et al.
Publicado: (2008)

Coexistence of Plasma Cell Dyscrasia with Prefibrotic Stage of Primary Myelofibrosis: A Case Report
por: Tsirakis, George, et al.
Publicado: (2011)

A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias
por: Lionetti, Marta, et al.
Publicado: (2015)

The Incidence of Senile Cataract and Glaucoma is Increased in Patients with Plasma Cell Dyscrasias: Etiologic Implications
por: Hemminki, Kari, et al.
Publicado: (2016)

A challenging diagnosis of a nonsecretor plasma cell dyscrasia with pleomorphic plasmablastic morphology
por: Van Landeghem, Stijn, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gic2maagotsh9ln51nkj2at46o